Find out what's happening in the area of Horizon Europe, Digital Europe and Horizon 2020
Starts in 2 weeks from now
LocationBrussels
This thematic workshop of the Community for European Research and Innovation for Security (CERIS) aims at presenting and discussing European research and innovative solutions, as well as further capability needs, relevant for countering trafficking and illicit trade in cultural goods across the European Union borders.
The interested audience includes security practitioners, especially customs and law enforcement authorities, innovators, operators in the cultural goods markets, national and EU policy makers on capabilities, such as those related to detection of threats in the flow of goods and services, and risk assessment. The workshop will bring together updates and EU-funded projects of innovative European technologies in this field; from relevant AI tools and web-crawlers to advanced and safe tracking and detection technologies that enhance the protection of cultural goods.
For more information on this event and registration, please access the dedicated event page via this link.
If you’re interested in information about the Horizon Europe Calls on the destination 'Effective Management of EU External Borders,' please don't hesitate to contact your NCP for Cluster 3, Fernanda Werneck (fernanda.werneck@vlaio.be)
We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).
Stay informed about what matters to you.
By signing up, you can opt in for e-mail notifications and get access to
a personalised dashboard that groups all news updates and event announcements in your domain(s).
Only for stakeholders located in Flanders
Security Digital, Industry & Space EDF
The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.